- InterCure (INCR.U) has signed a licensing agreement with Praetorian Global, Inc. to distribute Binske-branded products
- It allows InterCure to manufacture and distribute all Binske branded products under EU-GMP standards exclusively to the international pharmaceutical space
- InterCure engages in the research, cultivation, production, and distribution of pharma-grade cannabis-based products
- Intercure Ltd. (INCR.U) remains unchanged, trading at C$4.15 per share at 12:30 pm ET
InterCure (INCR.U) has signed a licensing agreement with Praetorian Global, Inc. to distribute Binske-branded products.
As per the agreement, Praetorian Global, Inc., based in Florida, and the parent company of the award-winning cannabis brand, Binske, has granted InterCure an exclusive multi-year right to cultivate, manufacture, market, and distribute Binske-branded products in major global pharmaceutical markets including Israel, Germany, Australia, UK and others.
InterCure believes Binske has pioneered the premium medical and recreational markets in the United States. The Binske brand has won numerous cannabis-related awards, including Leafly’s Best Overall Brand, Best Edibles and Best Concentrates.
The agreement brings these Binske-branded products exclusively to Intercure’s Israeli hub. It allows InterCure to manufacture and distribute all Binske branded products under EU-GMP standards exclusively to the international pharmaceutical space.
Binske will provide the company access to its intellectual property. It includes genetics, formulations and know-how for the cultivation and manufacturing of Binske-branded cannabis products at the company’s facilities. In addition, Binske will provide InterCure with IP relating to extraction formulations and the production of downstream products developed by Binske. It will also support InterCure’s team with training in manufacturing and cultivation methods that are tailored to Binske’s exacting standards.
InterCure engages in the research, cultivation, production, and distribution of pharma-grade cannabis-based products.
Intercure Ltd. (INCR.U) remains unchanged, trading at C$4.15 per share at 12:30 pm ET.